ASCO conference had significantly less of an impact on Oncologist future behavior

Asco impactIn June 2013, Encuity Research conducted an online study with 100 oncologists who attended the 2013 ASCO conference, to better understand perceptions about the conference and to assess how ASCO may impact future prescribing behavior. Among the key findings; Oncologists reported that the 2013 ASCO conference had significantly less of an impact on their future behavior than the 2012 conference. Just 16% of attendees reported that they are likely to change patient treatments based on this year’s ASCO conference, compared with 40% in 2012.

Asco Changes

Among the other key findings;

Products that had the strongest impact on physicians included the following:

  • 22% of physicians indicated that they will consider using more Avastin following the conference.
  • 10% of physicians reported that they would use more BMS/Lilly’s Erbitux® following the 2013 conference.
  • 9% of physicians indicated plans to extend use of AstraZeneca’s tamoxifen to 10 years (vs. current standard of 5 years).

Oncologists attending the 2013 ASCO conference reported that the most important pieces of clinical information presented at the conference were

  • New treatments for melanoma, with an emphasis on PD‐1 treatments (31% of mentions) – Advances in the treatment of cervical cancer, particularly Avastin® (20% of mentions).
  • ASCO attendees gave information presented on Genentech/Roche’s Avastin (bevacizumab) the highest overall ratings at ASCO, with 66% of attendees rating it as very or extremely valuable. Information on Bayer/Onyx’s Nexavar ® (sorafenib) in thyroid cancer received the second‐highest ratings (58%).
  • Information that received lower overall ratings for value included presentations on Merrimack’s MM‐398 and Amgen’s T‐VEC.

When asked which companies provided the most valuable information at the conference (unaided), Genentech was mentioned the most frequently by far (84% of attendees), followed by Bristol‐Myers Squibb with 43% of mentions.

  • – Novartis ranked third (29% of mentions).
  • – Merck ranked fourth (20%), followed by Celgene (16%).

ASCO Up and Coming

Oncologists named Millennium most often as an up‐and‐coming company in the treatment of cancer (13% of mentions); Seattle Genetics and Sanofi followed.

More than two thirds of physicians indicated that they visited the exhibit hall at the 2013 conference. Unaided, 29% indicated that Genentech/Roche had the most effective exhibit booth, followed by BMS (10%) and Amgen (8%).

Physicians gave the 2013 ASCO conference high ratings for overall value (5.4 on a 7‐point scale), with 86% of those who attended in 2012 rating this year’s conference as equal or better than the previous year’s conference.

Asco research

 

You can get more information and the report at

sniles@campbellalliance.com
http://www.campbellalliance.com

One thought on “ASCO conference had significantly less of an impact on Oncologist future behavior

  1. You really make it appear so easy along with your presentation however I find this matter
    to be actually one thing that I think I might by no means understand.
    It sort of feels too complex and very extensive for
    me. I am looking forward on your next post,
    I will attempt to get the grasp of it!

Leave a Reply

Your email address will not be published. Required fields are marked